YposKesi, the first French pharmaceutical company to develop and manufacture gene and cell therapy products for rare diseases, created by the nonprofit organization AFM-Téléthon and the SPI fund managed by Bpifrance, have announced the appointment of Alain Lamproye as its Chief Executive Officer. Alain Lamproye brings more than 25 years of experience in Europe and the United States in the field of industrial bioproduction. YposKesi will benefit from his unique expertise in bioproduction management and in the manufacturing of products generated from biotechnologies and gene therapy.
